Skip to main content

Advertisement

New targets for an old drug

Article metrics

Abstract

Methotrexate has been a clinical agent used in cancer, immunosuppression, rheumatoid arthritis, and other highly proliferative diseases for many years, yet its underlying molecular mechanism of action in these therapeutic areas is still unclear. We have previously reported using a chemical proteomics technique on several other potential pharmacodynamic targets of methotrexate. Here, using a frontal affinity chromatography with mass spectrometry detection, we confirm one of these targets, hypoxanthine-guanine amidophosphoribosyltransferase, as a true binder of methotrexate with a Kd of 4.2 μM. These results complement and confirm our recent study, but more importantly, shed light into the mechanism of action of methotrexate in oncology and other highly proliferative diseases and may help explain some unaccounted for effects of this drug. For example, despite the fact that DNA salvage pathway enzymes are highly active, methotrexate can be effective if it only targets enzymes of the de novo pathway.

References

  1. 1.

    Arlington, S.A. (2001). Industrialization of R&D in the 21st Century. Pricewaters Coopers, ECPI, Barcelona, Spain.

  2. 2.

    Banik, G.M. (2004, May). In silico ADME-Tox prediction: The more the merrier. Current Drug Discovery, pp. 31–34.

  3. 3.

    CHI. (2002, May). CHI's Third Annual Conference on Pharmacogenomics/Pharmacoproteomics Europe. Munich, Germany.

  4. 4.

    Leung, D., Hardouin, C., Boger, D.L., and Cravatt, B.F. (2003). Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21: 687–691.

  5. 5.

    Kim, E. and Park, J. M. (2003). Identification of novel target proteins of cyclic GMP signaling pathways using chemical proteomics. J. Biochem. Mol. Biol. 36:299–304.

  6. 6.

    Graves, P.R., Kwiek, J.J., Fadden, P., Ray, R., Hardeman, K., Coley, A.M., et al. (2002). Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62:1364–1372.

  7. 7.

    Weber, G. and Prajda, N. (1994). Targeted and non-targeted actions of anti-cancer drugs. Adv. Enzyme Regul. 34:71–89.

  8. 8.

    Allison, A.C. (2000). Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47:63–83.

  9. 9.

    Saravanan, V. and Hamilton, J. (2002). Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin. Pharmacother. 3:845–856.

  10. 10.

    Fairbanks, L.D., Ruckemann, K., Qiu, Y., Hawrylowicz, C.M., Richards, D.F., Swaminathan, R., et al. (1999). Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem. J. 342(Pt. 1):143–152.

  11. 11.

    Cronstein, B.N. (1997). The mechanism of action of methotrexate. Rheum. Dis. Clin. North Am. 23:739–755.

  12. 12.

    Costi, M.P. and Ferrari, S. (2001). Update on antifolate drugs targets. Curr. Drug Targets 2:135–166.

  13. 13.

    Allegra, C.J., Drake, J.C., Jolivet, J., and Chabner, B.A. (1985). Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA 82:4881–4885.

  14. 14.

    Mauritz, R., Peters, G.J., Priest, D.G., Assaraf, Y.G., Drori, S., Kathmann, I., et al. (2002). Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem. Pharmacol. 63:105–115.

  15. 15.

    Toledo-Sherman, L.M., Desouza, L., Hosfield, C., Liao, L., Boutellier, K., Taylor, P., et al. (2004). New targets for an old drug: a chemical proteomics approach to unraveling the molecular mechanism of action of methotrexate. Clin. Proteomics 1:45–68.

  16. 16.

    Jones, G., Willett, P., Glen, R.C., Leach, A.R., and Taylor, R. (1997). Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:727–748.

  17. 17.

    Chen, Y.Z. and Zhi, D.G. (2001). Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 43:217–226.

  18. 18.

    Chan, N.W.C., Lewis, D.F., Hewko, S., Hindsgaul, O., and Schriemer, D.C. (2002). Frontal affinity chromatography for the screening of mixtures. Comb. Chem. High Throughput Screen. 5:395–406.

  19. 19.

    Weber, G., Nagai, M., Natsumeda, Y., Ichikawa, S., Nakamura, H., Eble, J.N., et al. (1991). Regulation of de novo and salvage pathways in chemotherapy. Adv. Enzyme Regul. 31:45–67.

  20. 20.

    Balendiran, G.K., Molina, J.A., Xu, Y., Torres-Martinez, J., Stevens, R., Focia, P.J., et al. (1999). Ternary complex structure of human HGPRTase, PRPP, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. Protein Sci. 8:1023–1031.

  21. 21.

    Schoettle, S.L. and Christopherson, R.I. (1994). Inhibition of murine amido phosphoribosyl-transferase by folate derivatives. Adv. Exp. Med. Biol. 370:151–154.

  22. 22.

    Jones, R.J. and Twelves, C.J. (2002). Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Expert Rev. Anticancer Ther. 2:13–22.

  23. 23.

    Aherne, G.W., Hardcastle, A., Ward, E., Dobinson, D., Crompton, T., Valenti, M., et al. (2001). Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clin. Cancer Res. 7:2923–2930.

  24. 24.

    Romain, S., Martin, P.M., Klijn, J.G., van Putten, W.L., Look, M.P., Guirou, O., et al. (1997). DNA-synthesis enzyme activity: a biological tool useful for predicting antimetabolic drug sensitivity in breast cancer? Int. J. Cancer 74:156–161.

  25. 25.

    Weber, G. and Prajda, N. (1994). Targeted and non-targeted actions of anti-cancer drugs. Adv. Enzyme Regul. 34:71–89.

  26. 26.

    Gordon, R.B., Keough, D.T., and Emmerson, B.T. (1987). HPRT-deficiency associated with normal PRPP concentration and APRT activity. J. Inherit. Metab. Dis. 10:82–88.

  27. 27.

    Fung, K.P., Lam, W.P., Choy, Y.M., and Lee, C.Y. (1996). Effect of methotrexate on the intracellular phosphoribosyl pyrophosphate level and glucose transport of Ehrlich ascites tumor cells in vitro. Oncology 53:27–30.

  28. 28.

    Slon-Usakiewicz, J.J., Ng, W., Foster, J.E., Dai, J.-R., Deretey, E., Toledo-Sherman, L., et al. (2004). Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA. J. Med. Chem. 47:5094–5100.

Download references

Author information

Correspondence to Jacek J. Slon-Usakiewicz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Slon-Usakiewicz, J.J., Pasternak, A., Reid, N. et al. New targets for an old drug. Clin Proteom 1, 227–234 (2004) doi:10.1385/CP:1:3-4:227

Download citation

Key Words

  • Methotrexate
  • HGPRT
  • chemical
  • proteomics
  • mechanism of action